Coimbatore: RDIF and Serum institute of India, the world’s largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September.
Coimbatore: RDIF and Serum institute of India, the world’s largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September.
Technology transfer process has already started; cultivation process has begun following the approval by the Drug Controller General of India (DCGI). The parties intend to produce over 300 million doses of the vaccine in India per year with the first batch expected in September 2021.
Moscow, July 13, 2021 ~ The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, today announced cooperation to produce the Russian Sputnik vaccine against coronavirus. Sil is the world’s largest company in terms of COVID vaccines production with over 500 million doses manufactured. Through several strategic associations, Sil has been front running India’s fight against the pandemic.
In addition to developing its own vaccine, it is currently manufacturing Covishield (developed by AstraZeneca-Oxford), Covovax (by Novavax) and conducting trials of Codagenix in the UK. The first batch of Sputnik vaccine is expected to be produced at SIl's facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year. As part of the technical transfer process, Sil has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India (OCGI), the cultivation process has begun.
India is the leading production hub for production of Sputnik vaccine. RDIF had earlier reached agreements with a number of pharmaceulical companies in India (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma. Virchow Biotech and Morepen) for production of the Russian vaccine.
To date, Russian Sputnik V vaccine has been registered in 67 countries globally with a total population of over 3.5 bn people. The data obtained by regulators of a number of countries during the vaccination of the population, including in Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
Technology transfer process has already started; cultivation process has begun following the approval by the Drug Controller General of India (DCGI). The parties intend to produce over 300 million doses of the vaccine in India per year with the first batch expected in September 2021.
Moscow, July 13, 2021 ~ The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, today announced cooperation to produce the Russian Sputnik vaccine against coronavirus. Sil is the world’s largest company in terms of COVID vaccines production with over 500 million doses manufactured. Through several strategic associations, Sil has been front running India’s fight against the pandemic.
In addition to developing its own vaccine, it is currently manufacturing Covishield (developed by AstraZeneca-Oxford), Covovax (by Novavax) and conducting trials of Codagenix in the UK. The first batch of Sputnik vaccine is expected to be produced at SIl's facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year. As part of the technical transfer process, Sil has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India (OCGI), the cultivation process has begun.
India is the leading production hub for production of Sputnik vaccine. RDIF had earlier reached agreements with a number of pharmaceulical companies in India (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma. Virchow Biotech and Morepen) for production of the Russian vaccine.
To date, Russian Sputnik V vaccine has been registered in 67 countries globally with a total population of over 3.5 bn people. The data obtained by regulators of a number of countries during the vaccination of the population, including in Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.